Adverum Biotechnologies, Inc. (ADVM) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ADVM currently has 23.5M outstanding shares. with significant dilution risk as 77.5M authorized shares could dilute existing holders by 330.0%. The company has diluted shareholders by 18.09% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Dec 09, 2025 |
POS AM filing: This POS AM filing by Adverum Biotechnologies, Inc. deregisters all unsold securities from three previous registration statements (333-271431, 333-277634, and 333-278157) due to a merger with Eli Lilly and Company, which terminated all offerings and sales of securities. |
23M | 78M |
| Dec 09, 2025 |
POS AM filing: This POS AM filing by Adverum Biotechnologies, Inc. deregisters all unsold securities from three previous registration statements (333-271431, 333-277634, and 333-278157) due to a merger with Eli Lilly and Company, terminating all offerings and sales of securities. |
23M | 410M |
| Dec 09, 2025 |
POS AM filing: This POS AM filing by Adverum Biotechnologies, Inc. deregisters any and all securities that were registered but unsold or otherwise unissued under the previously filed Registration Statements on Form S-3 due to the merger with Eli Lilly and Company. |
23M | 420M |
| Nov 12, 2025 |
10-Q filing | 23.5M shares outstanding |
23M | 530M |
| Aug 12, 2025 |
10-Q filing | 21.0M shares outstanding |
21M | 530M |
| May 14, 2025 |
10-Q filing | 20.9M shares outstanding |
21M | 530M |
| Apr 15, 2025 |
10-K filing | 19.8M shares outstanding |
20M | 530M |
| Nov 04, 2024 |
10-Q filing | 20.9M shares outstanding |
21M | 530M |
| Aug 12, 2024 |
10-Q filing | 20.9M shares outstanding |
21M | 530M |
| May 09, 2024 |
10-Q filing | 20.8M shares outstanding |
21M | 530M |
| Mar 21, 2024 |
S-3 filing: Adverum Biotechnologies, Inc. may offer and sell up to an aggregate amount of $200,000,000 of any combination of common stock, preferred stock, debt securities and warrants. |
210M | 340M |
| Mar 18, 2024 |
10-K filing | 207.5M shares outstanding |
210M | 330M |
| Mar 04, 2024 |
S-3 filing: This S-3 filing covers the offer and resale of up to 106,480,057 shares of common stock by selling stockholders, including shares issuable upon exercise of pre-funded warrants, with the company not receiving proceeds from the sale but potentially receiving proceeds from warrant exercises. |
100M | 440M |
| Nov 09, 2023 |
10-Q filing | 101.0M shares outstanding |
100M | 330M |
| Aug 10, 2023 |
10-Q filing | 100.8M shares outstanding |
100M | 330M |
| May 11, 2023 |
10-Q filing | 100.3M shares outstanding |
100M | 330M |
| Apr 25, 2023 |
S-3 filing: Adverum Biotechnologies, Inc. may offer and sell up to an aggregate amount of $300,000,000 of any combination of common stock, preferred stock, debt securities and/or warrants. |
99M | 330M |
| Mar 30, 2023 |
10-K filing | 99.3M shares outstanding |
99M | 0 |
| Nov 10, 2022 |
10-Q filing | 99.5M shares outstanding |
99M | 0 |
| Aug 11, 2022 |
10-Q filing | 99.0M shares outstanding |
99M | 0 |
| May 12, 2022 |
10-Q filing | 98.6M shares outstanding |
99M | 0 |
| Mar 29, 2022 |
10-K filing | 98.0M shares outstanding |
98M | 0 |
| Nov 04, 2021 |
10-Q filing | 98.1M shares outstanding |
98M | 0 |
| Aug 05, 2021 |
10-Q filing | 98.0M shares outstanding |
98M | 0 |
| May 06, 2021 |
10-Q filing | 97.9M shares outstanding |
98M | 0 |
| Mar 01, 2021 |
10-K filing | 97.8M shares outstanding |
98M | 0 |
| Nov 05, 2020 |
10-Q filing | 97.5M shares outstanding |
97M | 0 |
| Aug 10, 2020 |
10-Q filing | 80.7M shares outstanding |
81M | 0 |
| May 28, 2020 |
10-Q filing | 80.3M shares outstanding |
80M | 0 |
| Mar 12, 2020 |
10-K filing | 79.7M shares outstanding |
80M | 0 |